LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH
Bio-Techne announced significant clinical data from its Lunaphore COMET spatial biology platform. The platform integrates with clinical research workflows and uses IHC-validated antibodies for rapid panel development. Research conducted with the National Tumor Institute and Nucleai revealed tumor microenvironment features that could predict therapy response in melanoma patients. The study combined multiplex immunofluorescence with AI-powered biomarker analysis, marking the first application of this technology in a clinical trial. Additional research with Johns Hopkins University demonstrated the platform's novel amplification technique for comprehensive tumor profiling.
Bio-Techne ha annunciato dati clinici significativi dalla sua piattaforma di biologia spaziale COMET di Lunaphore. La piattaforma si integra con i flussi di lavoro della ricerca clinica e utilizza anticorpi validati IHC per uno sviluppo rapido dei pannelli. La ricerca condotta con l'Istituto Nazionale dei Tumori e Nucleai ha rivelato caratteristiche del microambiente tumorale che potrebbero prevedere la risposta alla terapia nei pazienti con melanoma. Lo studio ha combinato l'immunofluorescenza multiplex con analisi di biomarker potenziate dall'IA, segnando la prima applicazione di questa tecnologia in uno studio clinico. Ulteriori ricerche con la Johns Hopkins University hanno dimostrato la tecnica di amplificazione innovativa della piattaforma per un profilo tumorale completo.
Bio-Techne anunció datos clínicos significativos de su plataforma de biología espacial COMET de Lunaphore. La plataforma se integra con los flujos de trabajo de investigación clínica y utiliza anticuerpos validados por IHC para el desarrollo rápido de paneles. La investigación realizada con el Instituto Nacional del Cáncer y Nucleai reveló características del microambiente tumoral que podrían predecir la respuesta a la terapia en pacientes con melanoma. El estudio combinó inmunofluorescencia multiplex con análisis de biomarcadores impulsados por IA, marcando la primera aplicación de esta tecnología en un ensayo clínico. Investigaciones adicionales con la Universidad Johns Hopkins demostraron la técnica de amplificación novedosa de la plataforma para un perfil tumoral integral.
Bio-Techne은 Lunaphore의 COMET 공간 생물학 플랫폼에서 중요한 임상 데이터를 발표했습니다. 이 플랫폼은 임상 연구 워크플로우와 통합되어 있으며, 신속한 패널 개발을 위해 IHC 검증된 항체를 사용합니다. 국립종양연구소와 Nucleai와 함께 수행된 연구는 흑색종 환자의 치료 반응을 예측할 수 있는 종양 미세환경 특징을 밝혀냈습니다. 이 연구는 AI 기반의 바이오마커 분석과 다중 면역 형광을 결합하여 이 기술이 임상 시험에 처음으로 적용되었음을 의미합니다. 또한 Johns Hopkins University와의 추가 연구로 포괄적인 종양 프로파일링을 위한 플랫폼의 혁신적인 증폭 기술이 입증되었습니다.
Bio-Techne a annoncé des données cliniques significatives provenant de sa plateforme de biologie spatiale COMET de Lunaphore. La plateforme s'intègre aux flux de travail de recherche clinique et utilise des anticorps validés par IHC pour un développement rapide des panneaux. Les recherches menées avec l'Institut National du Cancer et Nucleai ont révélé des caractéristiques du microenvironnement tumoral qui pourraient prédire la réponse thérapeutique chez les patients atteints de mélanome. L'étude a combiné l'immunofluorescence multiplex avec une analyse des biomarqueurs alimentée par l'IA, marquant la première application de cette technologie dans un essai clinique. Des recherches supplémentaires avec l'Université Johns Hopkins ont démontré la technique d'amplification novatrice de la plateforme pour un profilage complet des tumeurs.
Bio-Techne hat bedeutende klinische Daten von seiner COMET-Raum-Biologie-Plattform von Lunaphore veröffentlicht. Die Plattform integriert sich in klinische Forschungsabläufe und verwendet IHC-validierte Antikörper für eine schnelle Panelentwicklung. Forschungsarbeiten, die in Zusammenarbeit mit dem Nationalen Tumorinstitut und Nucleai durchgeführt wurden, zeigten Merkmale des Tumormikroenvironment, die die Therapieantwort bei Melanompatienten vorhersagen könnten. Die Studie kombinierte multiplexe Immunfluoreszenz mit KI-unterstützter Biomarker-Analyse und markiert die erste Anwendung dieser Technologie in einer klinischen Studie. Weitere Forschungen mit der Johns Hopkins University demonstrierten die neuartige Amplifikationstechnik der Plattform für eine umfassende Tumorprofilierung.
- Platform successfully integrated into clinical research workflows
- First-time application of the technology in a clinical trial setting
- Successful collaboration with major research institutions
- Platform demonstrated ability to predict therapy response
- None.
Insights
The launch of Bio-Techne's Lunaphore COMET spatial biology platform represents a significant advancement in clinical research capabilities. The platform's ability to use standard IHC-validated antibodies and integrate with clinical workflows reduces adoption barriers and operational costs. Key findings from collaborative studies with major institutions demonstrate practical applications in predicting immunotherapy responses in melanoma patients.
The platform's automation capabilities and AI integration for biomarker analysis position it strongly in the growing spatial biology market, estimated to reach
This development strengthens Bio-Techne's position in the high-growth spatial biology market. The COMET platform's integration with clinical workflows and compatibility with existing antibodies creates a compelling value proposition for research institutions and pharmaceutical companies. The collaboration with prominent institutions like Johns Hopkins and successful clinical trial applications validate the technology's commercial viability.
The platform's automation capabilities address key market demands for efficiency and reproducibility in clinical research. While immediate revenue impact may be gradual, the long-term potential is significant as spatial biology adoption increases in drug development and clinical research. The technology's demonstrated success in immunotherapy research particularly aligns with the growing
COMET, a best-in-class spatial biology platform, seamlessly integrates into standard clinical research workflows. Using off-the-shelf, clinically IHC-validated antibodies, new panels can be quickly developed and validated. Additionally, COMET enables high-plex workflow automation, adding unique value to clinical studies by facilitating robust and timely decision-making in treatment strategies.
Research conducted in collaboration with Prof. Paolo Ascierto, National Tumor Institute Fondazione G. Pascale, and leading AI-powered spatial biomarker and diagnostics company, Nucleai, uncovered potential tumor microenvironment (TME) features predictive of response to therapy. In the cohort study of immunotherapy-treated metastatic melanoma patients, a comprehensive spatial immuno-oncology multiplex immunofluorescence (mIF) panel was combined for the first time with advanced AI-powered biomarker analysis. The findings highlight that the fully- automated workflow and AI tissue analytics can be applied more broadly in immunotherapy drug development to enhance the understanding of treatment efficacy, ultimately improving patient outcomes.
"COMET enables the identification of multiple biomarkers and spatial interactions between different cell types within the TME," said Dr. Ascierto. "Its use together with Nucleai's AI spatial biomarker platform in predicting therapy response for patients enrolled in the SECOMBIT1 study, marks the first application of this innovative technology in a clinical trial, representing a significant step toward identifying predictive biomarkers."
"This study demonstrates our shared vision to accelerate predictive spatial biomarker development and showcases the COMET platform's unique potential in enabling the design of more effective immunotherapy strategies in advanced cancers such as metastatic melanoma, said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "We're committed to pushing the boundaries of healthcare by advancing spatial biology in clinical research and ultimately improve patient outcomes."
Another study conducted in collaboration with Prof. Janis Taube, Johns Hopkins University School of Medicine, demonstrates the potential of the novel amplification technique on the COMET platform, allowing scientists to comprehensively profile the TME, leading the way for improved insights in clinical research.
At this year's Society for Immunotherapy of Cancer's (SITC) Annual Meeting novel data sets will be presented, showcasing the scientific advancements brought by COMET.
To learn more about Lunaphore's poster presentations and activities at SITC, please visit: https://lunaphore.com/our-events
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Lunaphore
Lunaphore Technologies S.A. – a Bio-Techne brand, is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore's technology enables the identification of biomarker "signatures" with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. The multiomics capability of COMET™ enables the simultaneous analysis of both RNA and protein data within the spatial context of tissues to enhance the understanding of cellular dynamics and disease processes. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
Bio-Techne Corporation (NASDAQ: TECH)
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
For further information on Lunaphore:
Irene Tamayo, Senior Director, Product Strategy and Marketing
communications@lunaphore.com
1
An international study focusing on the different sequences of treatment in BRAF-mutated advanced melanoma patients.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lunaphore-comet-platform-paves-the-way-for-spatial-biology-adoption-in-clinical-research-302295964.html
SOURCE Bio-Techne Corporation
FAQ
What are the key features of Bio-Techne's COMET platform (TECH)?
What were the results of Bio-Techne's (TECH) melanoma study using COMET?
How is Bio-Techne (TECH) advancing spatial biology in clinical research?
